SCHEMBL9942986

SCHEMBL9942986

CN(C)C(=O)C(=O)N(C)C12CCC(CN3CCOCC3)(CC1)Cn1c2nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.50
KCNH2 Q12809 1/20 0.43
KMT2A Q03164 1/20 0.38
KCNE1 P15382 1/20 0.38
CCR1 P32246 1/20 0.38
KCNQ1 P51787 1/20 0.38
CNR2 P34972 1/20 0.36
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
HPGD P15428 2/20 0.35
RECQL P46063 2/20 0.35
LMNA P02545 2/20 0.35
GAA P10253 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
GLA P06280 1/20 0.35
MAPT P10636 1/20 0.35
TP53 P04637 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CASP1 P29466 1/20 0.34
CASP7 P55210 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9942978 0.92 CYP2C9 (0.51) CYP2C9KCNH2KMT2AKCNE1CCR1
SCHEMBL9942961 0.91 CYP2C9 (0.41) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL9943117 0.91 CYP2C9 (0.49) CYP2C9KCNH2KMT2AKCNE1CCR1
SCHEMBL14212631 0.90 CYP2C9 (0.48) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL9943054 0.88 CYP2C9 (0.51) CYP2C9KCNH2KMT2AKCNE1CCR1
SCHEMBL9901476 0.88 CYP2C9 (0.53) CYP2C9KCNH2KMT2AKCNE1CCR1
SCHEMBL9905078 0.88 CYP2C9 (0.53) CYP2C9KCNH2KMT2AKCNE1CCR1
SCHEMBL9943012 0.87 CYP2C9 (0.53) CYP2C9KCNH2KMT2AKCNE1CCR1
SCHEMBL14234672 0.87 CYP2C9 (0.53) CYP2C9KCNH2KMT2AKCNE1CCR1
SCHEMBL14119111 0.87 CYP2C9 (0.53) CYP2C9KCNH2KMT2AKCNE1CCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835411-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-09-16 US disclosed
US-8835411-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-09-16 US disclosed
US-20120309698-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2012-12-06 US disclosed
US-20120309698-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2012-12-06 US disclosed
WO-2012078834-A1 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309698-A1 HIV Integrase Inhibitors DNTT, POLB, UNG CYP2C9 602/4885KCNH2 3969/4885KMT2A 1339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.